Pharma CDMO Stock Jumps 20% After Former Cipla MD Umang Vohra Appointed as Executive Chairman and Group CEO

The Indian equity markets are trading in the green on Monday, with the Nifty 50 at 24,037.75, up 139.80 points or 0.58 per cent. Pharma stocks are also witnessing buying interest during the session. Amid this positive momentum, Cohance Lifesciences was trading at Rs 432.70, up Rs 72.10 or 19.99 per cent as of 9:43 AM, following a major leadership announcement by the company.

Cohance Lifesciences Leadership Update

Cohance Lifesciences has appointed Umang Vohra as Executive Chairman with effect from May 1, 2026, and as Group CEO from May 20, 2026, marking a significant leadership transition aimed at steering the company into its next phase of transformation and growth.

Mr Vohra succeeds Vivek Sharma, who is stepping down as Executive Chairman for personal reasons. However, Vivek Sharma will continue as an Advisor to the company for the next nine months to ensure a smooth transition.

The company stated that the appointment reflects a strategic Board decision to bring in a seasoned leader aligned with the demands of long-term scale-up and business transformation.

Leadership Profile of Umang Vohra

Umang Vohra brings more than three decades of experience in the pharmaceutical industry. Most recently, he served as the CEO and Managing Director of Cipla, where he led the company’s transformation over the last decade and helped build a diversified global pharmaceutical enterprise.

His appointment is being seen as a major positive for Cohance as the company looks to strengthen its global CDMO positioning and deepen customer partnerships.

Management Commentary

“I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance’s technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation,” said Umang Vohra.

Pankaj Patwari, Managing Director at Advent, added that Umang brings an owner-manager mindset, global stature, operational depth, and a proven track record of leading large-scale transformations in the pharmaceutical industry.

Shareholding Pattern Update

As per the latest March 2026 shareholding pattern, Foreign Institutional Investors reduced their holding to 5.59 per cent from 6.01 per cent in the previous quarter.

Meanwhile, Domestic Institutional Investors increased stake to 21.79 per cent from 21.57 per cent, indicating gradual domestic institutional accumulation despite the company’s weak long-term stock performance.

About Cohance Lifesciences

Cohance Lifesciences, formerly known as Suven Pharmaceuticals, is a technology-led global Contract Development and Manufacturing Organisation (CDMO) headquartered in Hyderabad. The company operates 14 manufacturing plants and 7 R&D facilities, employs over 3,000 people including 510+ scientists, and serves customers across 25 countries.

Exports contribute more than 90 per cent of total turnover, and the business operates through three focused verticals Pharma CDMO, API+, and Specialty Chemicals giving it a diversified presence across the pharmaceutical value chain.

Share your thoughts in the comments below.
Disclaimer: This article is for informational purposes only and not investment advice